Evaluation of Docking Machine Learning and Molecular Dynamics Methodologies for DNA-Ligand Systems.
Tiago Alves de OliveiraLucas Rolim MedagliaEduardo Habib Bechelane MaiaLetícia Cristina AssisPaulo Batista de CarvalhoAlisson Marques da SilvaAlex Gutterres TarantoPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
DNA is a molecular target for the treatment of several diseases, including cancer, but there are few docking methodologies exploring the interactions between nucleic acids with DNA intercalating agents. Different docking methodologies, such as AutoDock Vina, DOCK 6, and Consensus, implemented into Molecular Architect (MolAr), were evaluated for their ability to analyze those interactions, considering visual inspection, redocking, and ROC curve. Ligands were refined by Parametric Method 7 (PM7), and ligands and decoys were docked into the minor DNA groove (PDB code: 1VZK). As a result, the area under the ROC curve (AUC-ROC) was 0.98, 0.88, and 0.99 for AutoDock Vina, DOCK 6, and Consensus methodologies, respectively. In addition, we proposed a machine learning model to determine the experimental ∆T m value, which found a 0.84 R 2 score. Finally, the selected ligands mono imidazole lexitropsin ( 42 ), netropsin ( 45 ), and N , N '-(1H-pyrrole-2,5-diyldi-4,1-phenylene)dibenzenecarboximidamide ( 51 ) were submitted to Molecular Dynamic Simulations (MD) through NAMD software to evaluate their equilibrium binding pose into the groove. In conclusion, the use of MolAr improves the docking results obtained with other methodologies, is a suitable methodology to use in the DNA system and was proven to be a valuable tool to estimate the ∆T m experimental values of DNA intercalating agents.
Keyphrases
- polycyclic aromatic hydrocarbons
- molecular dynamics
- circulating tumor
- single molecule
- cell free
- machine learning
- density functional theory
- molecular dynamics simulations
- nucleic acid
- protein protein
- artificial intelligence
- deep learning
- transcription factor
- air pollution
- big data
- combination therapy
- risk assessment